Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.

Brudno JN, Lam N, Vanasse D, Shen YW, Rose JJ, Rossi J, Xue A, Bot A, Scholler N, Mikkilineni L, Roschewski M, Dean R, Cachau R, Youkharibache P, Patel R, Hansen B, Stroncek DF, Rosenberg SA, Gress RE, Kochenderfer JN.

Nat Med. 2020 Feb;26(2):270-280. doi: 10.1038/s41591-019-0737-3. Epub 2020 Jan 20.

PMID:
31959992
2.

The development of liquid biopsy for research and clinical practice in lymphomas: Report of the 15-ICML workshop on ctDNA.

Rossi D, Kurtz DM, Roschewski M, Cavalli F, Zucca E, Wilson WH.

Hematol Oncol. 2020 Feb;38(1):34-37. doi: 10.1002/hon.2704. Epub 2019 Dec 30.

PMID:
31872890
3.

Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction.

Kurtz DM, Esfahani MS, Scherer F, Soo J, Jin MC, Liu CL, Newman AM, Dührsen U, Hüttmann A, Casasnovas O, Westin JR, Ritgen M, Böttcher S, Langerak AW, Roschewski M, Wilson WH, Gaidano G, Rossi D, Bahlo J, Hallek M, Tibshirani R, Diehn M, Alizadeh AA.

Cell. 2019 Jul 25;178(3):699-713.e19. doi: 10.1016/j.cell.2019.06.011. Epub 2019 Jul 4.

PMID:
31280963
4.

Hybrid dosing of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed/refractory mantle cell lymphoma and diffuse large B-cell lymphoma.

Miljkovic MD, Roschewski M, Dunleavy K, Wilson WH.

Leuk Lymphoma. 2019 Dec;60(13):3320-3323. doi: 10.1080/10428194.2019.1627540. Epub 2019 Jun 17. No abstract available.

PMID:
31204529
5.

Liquid biopsy in non-Hodgkin's lymphoma.

Melani C, Wilson WH, Roschewski M.

Hematol Oncol. 2019 Jun;37 Suppl 1:70-74. doi: 10.1002/hon.2587. Review.

PMID:
31187522
6.

One Size Does Not Fit All: Who Benefits From Maintenance After Frontline Therapy for Follicular Lymphoma?

Roschewski M, Hill BT.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:467-476. doi: 10.1200/EDBK_239065. Epub 2019 May 17. Review.

7.

Management of adults with Burkitt lymphoma.

Gastwirt JP, Roschewski M.

Clin Adv Hematol Oncol. 2018 Dec;16(12):812-822. Review.

PMID:
30843890
8.

Reply to J. Wang et al.

Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Newman AM, Dührsen U, Hüttmann A, Meignan M, Casasnovas O, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA.

J Clin Oncol. 2019 Mar 20;37(9):755-757. doi: 10.1200/JCO.18.01907. Epub 2019 Feb 12. No abstract available.

PMID:
30753108
9.

Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas.

Roswarski J, Roschewski M, Melani C, Pittaluga S, Lucas A, Steinberg SM, Jaffe ES, Waldmann TA, Wilson WH.

Leuk Lymphoma. 2019 Aug;60(8):2062-2066. doi: 10.1080/10428194.2018.1562184. Epub 2019 Jan 10.

PMID:
30626252
10.

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.

Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH.

Lancet Haematol. 2018 Dec;5(12):e609-e617. doi: 10.1016/S2352-3026(18)30177-7.

11.

Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial.

Kazandjian D, Korde N, Mailankody S, Hill E, Figg WD, Roschewski M, Landgren O.

JAMA Oncol. 2018 Dec 1;4(12):1781-1783. doi: 10.1001/jamaoncol.2018.5457. No abstract available.

12.

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.

Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, Tran T, Lynn J, Chen JY, Volkmer JP, Agoram B, Huang J, Majeti R, Weissman IL, Takimoto CH, Chao MP, Smith SM.

N Engl J Med. 2018 Nov 1;379(18):1711-1721. doi: 10.1056/NEJMoa1807315.

PMID:
30380386
13.

Monitoring clinical outcomes in aggressive B-cell lymphoma: From imaging studies to circulating tumor DNA.

Melani C, Wilson WH, Roschewski M.

Best Pract Res Clin Haematol. 2018 Sep;31(3):285-292. doi: 10.1016/j.beha.2018.07.004. Epub 2018 Jul 3. Review.

PMID:
30213398
14.

Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.

Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Levy R, Newman AM, Dührsen U, Hüttmann A, Meignan M, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA.

J Clin Oncol. 2018 Oct 1;36(28):2845-2853. doi: 10.1200/JCO.2018.78.5246. Epub 2018 Aug 20.

15.

End-of-treatment and serial PET imaging has prognostic value and clinical utility in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R - Response to Adams et al.

Melani C, Roschewski M, Wilson WH.

Haematologica. 2018 Aug;103(8):e382. doi: 10.3324/haematol.2018.199547. No abstract available.

16.

End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making.

Melani C, Advani R, Roschewski M, Walters KM, Chen CC, Baratto L, Ahlman MA, Miljkovic MD, Steinberg SM, Lam J, Shovlin M, Dunleavy K, Pittaluga S, Jaffe ES, Wilson WH.

Haematologica. 2018 Aug;103(8):1337-1344. doi: 10.3324/haematol.2018.192492. Epub 2018 May 10.

17.

What is the standard of care for primary mediastinal b-cell lymphoma; R-CHOP or DA-EPOCH-R?

Melani C, Wilson WH, Roschewski M.

Br J Haematol. 2019 Mar;184(5):836-838. doi: 10.1111/bjh.15185. Epub 2018 Mar 13. No abstract available.

PMID:
29532904
18.

Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma.

Mailankody S, Kazandjian D, Korde N, Roschewski M, Manasanch E, Bhutani M, Tageja N, Kwok M, Zhang Y, Zingone A, Lamy L, Costello R, Morrison C, Hultcrantz M, Christofferson A, Washington M, Boateng M, Steinberg SM, Stetler-Stevenson M, Figg WD, Papaemmanuil E, Wilson WH, Keats JJ, Landgren O.

Blood Adv. 2017 Sep 29;1(22):1911-1918. doi: 10.1182/bloodadvances.2017005934. eCollection 2017 Oct 10.

19.

Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas.

Roswarski J, Roschewski M, Lucas A, Melani C, Pittaluga S, Jaffe ES, Steinberg SM, Waldmann TA, Wilson WH.

Leuk Lymphoma. 2018 Jun;59(6):1466-1469. doi: 10.1080/10428194.2017.1387908. Epub 2017 Oct 16. No abstract available.

20.

Host-related immunodeficiency in the development of multiple myeloma.

Dosani T, Mailankody S, Korde N, Manasanch E, Bhutani M, Tageja N, Roschewski M, Kwok M, Kazandjian D, Costello R, Burton D, Zhang Y, Liewehr D, Steinberg SM, Maric I, Landgren O.

Leuk Lymphoma. 2018 May;59(5):1127-1132. doi: 10.1080/10428194.2017.1361026. Epub 2017 Aug 9.

21.

PD-1 Blockade in Mediastinal Gray-Zone Lymphoma.

Melani C, Major A, Schowinsky J, Roschewski M, Pittaluga S, Jaffe ES, Pack SD, Abdullaev Z, Ahlman MA, Kwak JJ, Morgan R, Rabinovitch R, Pan Z, Haverkos BM, Gutman JA, Pollyea DA, Smith CA, Wilson WH, Kamdar M.

N Engl J Med. 2017 Jul 6;377(1):89-91. doi: 10.1056/NEJMc1704767. No abstract available.

22.

MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R.

Lai C, Roschewski M, Melani C, Pittaluga S, Shovlin M, Steinberg SM, Dunleavy K, Pack S, Jaffe ES, Wilson WH.

Leuk Lymphoma. 2018 Feb;59(2):505-508. doi: 10.1080/10428194.2017.1339882. Epub 2017 Jun 22. No abstract available.

23.

Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.

Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, Yang Y, Cole DE, Melani C, Higham CS, Desai JV, Ceribelli M, Chen L, Thomas CJ, Little RF, Gea-Banacloche J, Bhaumik S, Stetler-Stevenson M, Pittaluga S, Jaffe ES, Heiss J, Lucas N, Steinberg SM, Staudt LM, Wilson WH.

Cancer Cell. 2017 Jun 12;31(6):833-843.e5. doi: 10.1016/j.ccell.2017.04.012. Epub 2017 May 25.

24.

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.

Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, Xue A, Goff SL, Yang JC, Sherry RM, Klebanoff CA, Kammula US, Sherman M, Perez A, Yuan CM, Feldman T, Friedberg JW, Roschewski MJ, Feldman SA, McIntyre L, Toomey MA, Rosenberg SA.

J Clin Oncol. 2017 Jun 1;35(16):1803-1813. doi: 10.1200/JCO.2016.71.3024. Epub 2017 Mar 14.

25.

Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone.

Manasanch EE, de Larrea CF, Zingone A, Steinberg SM, Kwok M, Tageja N, Bhutani M, Kazandjian D, Roschewski M, Wu P, Carter G, Zuchlinski D, Mulquin M, Lamping L, Costello R, Burton D, Gil LA, Figg WD, Maric I, Calvo KR, Yuan C, Stetler-Stevenson M, Korde N, Landgren O.

Leuk Lymphoma. 2017 Mar;58(3):639-645. doi: 10.1080/10428194.2016.1214953. Epub 2016 Aug 9.

26.

Molecular Monitoring of Cell-Free Circulating Tumor DNA in Non-Hodgkin Lymphoma.

Melani C, Roschewski M.

Oncology (Williston Park). 2016 Aug;30(8):731-8, 744. Review.

27.

Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas.

Kwok M, Wu SP, Mo C, Summers T, Roschewski M.

Curr Treat Options Oncol. 2016 Sep;17(9):47. doi: 10.1007/s11864-016-0425-1. Review.

PMID:
27461036
28.

Precision monitoring takes the stage.

Roschewski M.

Blood. 2016 Jul 14;128(2):149-50. doi: 10.1182/blood-2016-05-717520. No abstract available.

29.

Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma.

Saba NS, Liu D, Herman SE, Underbayev C, Tian X, Behrend D, Weniger MA, Skarzynski M, Gyamfi J, Fontan L, Melnick A, Grant C, Roschewski M, Navarro A, Beà S, Pittaluga S, Dunleavy K, Wilson WH, Wiestner A.

Blood. 2016 Jul 7;128(1):82-92. doi: 10.1182/blood-2015-11-681460. Epub 2016 Apr 28.

30.

Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma.

Roschewski M, Staudt LM, Wilson WH.

Blood. 2016 Jun 23;127(25):3127-32. doi: 10.1182/blood-2016-03-635219. Epub 2016 Apr 14. Review.

31.

Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging.

Bhutani M, Turkbey B, Tan E, Korde N, Kwok M, Manasanch EE, Tageja N, Mailankody S, Roschewski M, Mulquin M, Carpenter A, Lamping E, Minter AR, Weiss BM, Mena E, Lindenberg L, Calvo KR, Maric I, Usmani SZ, Choyke PL, Kurdziel K, Landgren O.

Leuk Lymphoma. 2016 May;57(5):1114-21. doi: 10.3109/10428194.2015.1090572. Epub 2016 Apr 7.

32.

Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma.

Dunleavy K, Pittaluga S, Shovlin M, Roschewski M, Lai C, Steinberg SM, Jaffe ES, Wilson WH.

Haematologica. 2016 Jan;101(1):e27-9. doi: 10.3324/haematol.2015.131151. Epub 2015 Oct 30. No abstract available.

33.

Monitoring lymphoma patients after therapy.

Roschewski M.

Clin Adv Hematol Oncol. 2015 May;13(5):277-9. No abstract available.

PMID:
26352768
34.

Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.

Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M, Tageja N, Kazandjian D, Mailankody S, Wu P, Morrison C, Costello R, Zhang Y, Burton D, Mulquin M, Zuchlinski D, Lamping L, Carpenter A, Wall Y, Carter G, Cunningham SC, Gounden V, Sissung TM, Peer C, Maric I, Calvo KR, Braylan R, Yuan C, Stetler-Stevenson M, Arthur DC, Kong KA, Weng L, Faham M, Lindenberg L, Kurdziel K, Choyke P, Steinberg SM, Figg W, Landgren O.

JAMA Oncol. 2015 Sep;1(6):746-54. doi: 10.1001/jamaoncol.2015.2010.

35.

Secondary diffuse large B-cell lymphoma of the central nervous system: the need for better predictors.

Roschewski M, Dunleavy K.

Leuk Lymphoma. 2015 Jun;56(6):1583-4. doi: 10.3109/10428194.2015.1016936. No abstract available.

PMID:
26099732
36.

Mantle Cell Lymphoma: An Evolving Therapeutic Landscape.

Roschewski M.

Fed Pract. 2015 May;32(Suppl 4):50S-53S.

37.

Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study.

Roschewski M, Dunleavy K, Pittaluga S, Moorhead M, Pepin F, Kong K, Shovlin M, Jaffe ES, Staudt LM, Lai C, Steinberg SM, Chen CC, Zheng J, Willis TD, Faham M, Wilson WH.

Lancet Oncol. 2015 May;16(5):541-9. doi: 10.1016/S1470-2045(15)70106-3. Epub 2015 Apr 1. Erratum in: Lancet Oncol. 2015 May;16(5):e199.

38.

Cracking the diverse biologic code of diffuse large B-cell lymphoma.

Roschewski M, Wilson WH.

Semin Hematol. 2015 Apr;52(2):55-6. doi: 10.1053/j.seminhematol.2015.01.010. Epub 2015 Jan 21. No abstract available.

PMID:
25805584
39.

Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials.

Manasanch EE, Korde N, Mailankody S, Tageja N, Bhutani M, Roschewski M, Landgren O.

Haematologica. 2014 Dec;99(12):1769-71. doi: 10.3324/haematol.2014.107516. No abstract available.

40.

Precision treatment of distinct molecular subtypes of diffuse large B-cell lymphoma: ascribing treatment based on the molecular phenotype.

Dunleavy K, Roschewski M, Wilson WH.

Clin Cancer Res. 2014 Oct 15;20(20):5182-93. doi: 10.1158/1078-0432.CCR-14-0497. Review.

41.

Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method.

Manasanch EE, Salem DA, Yuan CM, Tageja N, Bhutani M, Kwok M, Kazandjian D, Carter G, Steinberg SM, Zuchlinski D, Mulquin M, Calvo K, Maric I, Roschewski M, Korde N, Braylan R, Landgren O, Stetler-Stevenson M.

Leuk Lymphoma. 2015 May;56(5):1416-24. doi: 10.3109/10428194.2014.955020. Epub 2014 Oct 30.

42.

Intraocular (vitreoretinal) lymphoma with renal, pelvic, and central nervous system lesions.

Bhatt N, Fox A, Chan CC, Roschewski M, Sen HN.

Can J Ophthalmol. 2014 Aug;49(4):e104-6. doi: 10.1016/j.jcjo.2014.05.009. Epub 2014 Jul 17. No abstract available.

PMID:
25103663
43.

Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease.

Zingone A, Wang W, Corrigan-Cummins M, Wu SP, Plyler R, Korde N, Kwok M, Manasanch EE, Tageja N, Bhutani M, Mulquin M, Zuchlinski D, Yancey MA, Roschewski M, Zhang Y, Roccaro AM, Ghobrial IM, Calvo KR, Landgren O.

Cytokine. 2014 Oct;69(2):294-7. doi: 10.1016/j.cyto.2014.05.017. Epub 2014 Jul 17.

44.

A prospective study of mediastinal gray-zone lymphoma.

Wilson WH, Pittaluga S, Nicolae A, Camphausen K, Shovlin M, Steinberg SM, Roschewski M, Staudt LM, Jaffe ES, Dunleavy K.

Blood. 2014 Sep 4;124(10):1563-9. doi: 10.1182/blood-2014-03-564906. Epub 2014 Jul 14.

45.

Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis.

Weiss BM, Hebreo J, Cordaro DV, Roschewski MJ, Baker TP, Abbott KC, Olson SW.

J Clin Oncol. 2014 Sep 1;32(25):2699-704. doi: 10.1200/JCO.2013.50.0892. Epub 2014 Jul 14.

46.

Management of heavy chain diseases: the challenges of biologic heterogeneity.

Roschewski M, Manasanch EE, Wilson WH.

Oncology (Williston Park). 2014 Jan;28(1):63-5. No abstract available.

47.

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.

Korde N, Carlsten M, Lee MJ, Minter A, Tan E, Kwok M, Manasanch E, Bhutani M, Tageja N, Roschewski M, Zingone A, Costello R, Mulquin M, Zuchlinski D, Maric I, Calvo KR, Braylan R, Tembhare P, Yuan C, Stetler-Stevenson M, Trepel J, Childs R, Landgren O.

Haematologica. 2014 Jun;99(6):e81-3. doi: 10.3324/haematol.2013.103085. Epub 2014 Mar 21. No abstract available.

48.

Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases.

Tembhare PR, Yuan CM, Venzon D, Braylan R, Korde N, Manasanch E, Zuchlinsky D, Calvo K, Kurlander R, Bhutani M, Tageja N, Maric I, Mulquin M, Roschewski M, Kwok M, Liewehr D, Landgren O, Stetler-Stevenson M.

Leuk Res. 2014 Mar;38(3):371-6. doi: 10.1016/j.leukres.2013.12.007. Epub 2013 Dec 11.

49.

Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey.

Landgren O, Graubard BI, Katzmann JA, Kyle RA, Ahmadizadeh I, Clark R, Kumar SK, Dispenzieri A, Greenberg AJ, Therneau TM, Melton LJ 3rd, Caporaso N, Korde N, Roschewski M, Costello R, McQuillan GM, Rajkumar SV.

Leukemia. 2014 Jul;28(7):1537-42. doi: 10.1038/leu.2014.34. Epub 2014 Jan 20.

50.

Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma.

Roschewski M, Dunleavy K, Wilson WH.

Leuk Lymphoma. 2014 Nov;55(11):2428-37. doi: 10.3109/10428194.2014.883075. Epub 2014 Mar 7. Review.

PMID:
24438195

Supplemental Content

Loading ...
Support Center